AUS
NZ
UK
CA
USA
IND
Highlights:
- Strong Revenue Growth: Sensus Healthcare saw a 127% year-over-year increase in Q3 2024 revenues.
- Profitability Shift: The company posted a net income of $1.2 million, reversing a loss from the prior year.
- Strategic Expansion: 27 systems shipped and 7 new Fair Deal Agreements signed for SRT-100 Vision units.
Sensus Healthcare (NASDAQ:SRTS) has reported impressive financial results for the third quarter of 2024, highlighting significant growth in both revenue and profitability. The company achieved total revenues of $8.8 million for Q3 2024, marking a remarkable 127% increase from $3.9 million in the same quarter last year. This surge in revenue is driven by strong demand for its SRT-100 Vision systems, which are used in non-invasive skin cancer treatment.
In addition to strong revenue growth, Sensus Healthcare transitioned from a net loss to profitability in Q3 2024. The company reported a net income of $1.2 million, or $0.07 per diluted share, compared to a net loss of $1.5 million for the same period in 2023. This turnaround reflects the company’s successful expansion and operational improvements.
One of the standout metrics from the earnings report is the improvement in Sensus' gross profit margin, which increased to 59.3% in Q3 2024, up from 51.0% in Q3 2023. The boost in profitability is attributed to both higher sales volume and better operational efficiency.
Sensus also reported a robust balance sheet with $22.6 million in cash and no outstanding debt, positioning the company well for future growth and expansion. The company’s financial health has enabled it to pursue its growth strategy aggressively. In the third quarter, Sensus shipped 27 systems, up from just 11 systems in Q3 2023, reflecting strong demand for its products.
The company has also made significant progress in its recurring-revenue business model. Since March 2024, Sensus has signed 22 new Fair Deal Agreements for its SRT-100 Vision systems, bringing the total number of such agreements to 50 by the end of the year. These agreements provide a steady stream of income, contributing to long-term growth.
While the financial results are largely positive, there are some concerns. Sensus reported an increase in accounts receivable, which rose to $17.0 million from $10.6 million in the previous year. This increase was largely due to extended payment terms with customers, which may lead to potential liquidity issues in the short term. Additionally, higher bad debt expenses were reported in Q3 2024, which could impact future earnings if the trend continues.
